Hypertension and Cholesterol in the Elderly

Similar documents
Hypertension in the very old. Objectives: Clinical Perspective

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Hypertension Management Controversies in the Elderly Patient

Lipid Management 2013 Statin Benefit Groups

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Objectives. Describe results and implications of recent landmark hypertension trials

RESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Blood Pressure LIMBO How Low To Go?

Disclosures. Hypertension: Nationwide Dilemma. Learning Objectives. What s Currently Recommended? Specific Concerns 3/9/2012

Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

Hypertension Management: A Moving Target

Hypertension and the SPRINT Trial: Is Lower Better

TIP. Documentation and coding guide. Disease definitions* Prevalence and statistics associated with HTN**

Renal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School

Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s

Brent M. Egan, MD Professor of Medicine USCSOM Greenville

Disclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

No relevant financial relationships

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

What s In the New Hypertension Guidelines?

Statins after 80 years old. Pros/Cons symposium. 13 th EUGMS Congress Nice Sept 2017

가정혈압의활용 CARDIOVASCULAR CENTER. Wook Bum Pyun M.D., Ph.D. HOME BLOOD PRESSURE MONITORING. Ewha Womans University, school of Medicine

HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS

T. Suithichaiyakul Cardiomed Chula

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.

Using the New Hypertension Guidelines

No relevant financial relationships

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

Dyslipidemia and Combination Therapy: A Framework for Clinical Decision Making

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

Treating Hypertension in 2018: What Makes the Most Sense Today?

CONTRIBUTING FACTORS FOR STROKE:

What do the guidelines say about combination therapy?

4/24/15. AHA/ACC 2013 Guideline Key Points

Diabetes Mellitus: A Cardiovascular Disease

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

ADVANCES IN MANAGEMENT OF HYPERTENSION

Drugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events

New Cholesterol Guidelines What the LDL are we supposed to do now?!

Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk

major public health burden

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly

Systemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

Implementation of JNC- 8 Hypertension Recommendations: Combining evidence and value-based practice strategies for accountable care

Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD

The ABCs (A1C, BP and Cholesterol) of Diabetes

Managing Hypertension in 2016

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

American Diabetes Association 2018 Guidelines Important Notable Points

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

HYPERTENSION: ARE WE GOING TOO LOW?

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

Treatment of Cholesterol in 2018: Time to Level Up. Most Important Slide. Three Things Learned that Will be Applied

Recent Hypertension Guidelines

Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines

Objectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence

5.2 Key priorities for implementation

The New Hypertension Guidelines

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016

Ambulatory BP Monitoring: Getting the Diagnosis of Hypertension Right. Anthony J. Viera, MD, MPH, FAHA Professor and Chair

Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

Snapshot. What kinds of things make you feel stressed out? What do you do to calm back down? Do you have any good tricks for de-stressing??

How would you manage Ms. Gold

Update on Cholesterol Management: The 2013 ACC/AHA Guidelines

Updates in Cardiovascular Recommendations for Diabetic Patients

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

Managing HTN in the Elderly: How Low to Go

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes

NEW GUIDELINES FOR CHOLESTEROL

Hypertension JNC 8 (2014)

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence

New Guidelines in Dyslipidemia Management

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents

DEPARTMENT OF GENERAL MEDICINE WELCOMES

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

The Latest Generation of Clinical

Hypertension Update Clinical Controversies Regarding Age and Race

Learning Objectives. Patient Case

Lipid Panel Management Refresher Course for the Family Physician

Game Strategy: High Intensity Statin in Stroke. K.M. Osei MD, MSc Cardiovascular Conference PARMC Feb 24, 2018

Blood Pressure Targets: Where are We Now?

New Hypertension Guidelines. Kofi Osei, MD

Transcription:

Hypertension and Cholesterol in the Elderly Angela Sanford, MD Assistant Professor of Geriatrics Saint Louis University School of Medicine I have no relevant financial disclosures Cushman WC. The burden of uncontrolled hypertension: morbidity and mortality associated with disease progression. J Clin Hypertens. 2003;5(suppl):14 22. Hypertension in the Elderly 1

WHAT IS THE IDEAL BLOOD PRESSURE FOR OUR ELDERLY PATIENTS? From: 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) JAMA. 2014;311(5):507-520. doi:10.1001/jama.2013.284427 2

Age Specific Differences Between Conventional and Ambulatory Daytime Blood Pressure Values., 2014 American Heart Association, Inc. Published by American Heart Association. 2 From: Treatment With Multiple Blood Pressure Medications, Achieved Blood Pressure, and Mortality in Older Nursing Home Residents: The PARTAGE Study JAMA Intern Med. Published online February 16, 2015. doi:10.1001/jamainternmed.2014.8012 Date of download: 5/14/2015 Copyright 2015 American Medical Association. All rights reserved. TREATMENT 3

How effective is the low sodium diet? Blood Pressure In this modeling study, 1.65 million deaths from cardiovascular causes that occurred in 2010 were attributed to sodium consumption above a reference level of 2.0 g per day. Mozaffarian D et al. N Engl J Med 2014;371:624-634. Pharmacologic Treatment Pharmacologic Treatment Medication selection principles (my opinion) Use cheapest drugs Simplest regimen possible Start one agent, maximize, then add additional agent if necessary Try to avoid medications that need to be taken two and three times/day if possible 4

Pseudohypertension AKA Noncompressibility Artery Syndrome Falsely elevated BP reading due to calcified blood vessels Suspect in those with: Persistently elevated BP w/ no evidence of endorgan damage Symptoms of overtreatment (lightheadedness, falls) Osler Maneuver: Inflate BP cuff until radial pulse is obliterated. If Orthostatic Hypotension Defined as a decrease in systolic BP by >20 mmhg or decrease in diastolic BP by >10 mmhg within 3 minutes of standing Results from inadequate 5

Orthostatic Hypotension Can cause lightheadedness, dizziness, syncope, weakness, fatigue, falls Exacerbated by Age Many, many meds (BP meds, antidepressants, gabapentin, anti dementia meds) Dehydration/vol depletion Anemia Parkinson s Disease Orthostatic Hypotension Measure standing BP in ALL older persons Treatment: Orthostatic Hypotension 6

One thing to keep in mind. Obstructive Sleep Apnea: Is a common cause of HTN, especially new onset HTN Increases catecholamines and cortisol Should ask about snoring, daytime somnolence Makes existing HTN difficult to control (often need multiple agents) Switching gears. CHOLESTEROL IN THE ELDERLY 7

Stone N, Robinson J, et al. 2013 ACC/AHC Guideline on the treatment of blood cholesterol to reduce atherosclerotic heart risk in adults. JACC 2013; doi:10.1016/j.jacc.2013.11.00 2 Background on New Guidelines Developed using randomized controlled trial (RCT) data from numerous studies Basis: Higher LDL increased risk of CVD and lowering LDL will decrease events Absolute reduction of events is proportional to baseline absolute risk Statins are drug of choice, as evidence is lacking on efficacy of other lipid lowering meds Small mention of lifestyle modification More Background High Intensity: Lowers LDL by >50% Atorvastatin 40 80 mg Rosuvastatin 20 40 mg Moderate Intensity: Lowers LDL by 30 50% Atorvastatin 10 20 mg Rosuvastatin 5 10 mg Pravastatin 40 80 mg 8

Now onto the Guidelines what do they say? New Cholesterol Guidelines 4 groups that would benefit from statins (CVD risk reduction outweighs statin adverse effect risk) identified: 1. Those with clinical hx of CVD (prior MI/CAD/stroke/TIA/PAD) secondary prevention 2. Those w/ LDL levels >190 mg/dl Stone N, Robinson 3. Diabetics J, et al. 2013 ACC/AHC age Guideline 40 75 on the treatment w/ of blood LDL cholesterol of 70 189 to reduce atherosclerotic without heart risk in adults. JACC 2013; doi:10.1016/j.jacc.2013.11.002 known CVD Stone N, Robinson J, et al. 2013 ACC/AHC Guideline on the treatment of blood cholesterol to reduce atherosclerotic heart risk in adults. JACC 2013; doi:10.1016/j.jacc.2013.11.002 9

What s this Risk Calculator? How Do These Apply to Our Elderly Patients? Few trials have included pts > 75 y/o The little data available do not support initiation of high intensity statin tx for secondary prevention in those >75 (adverse side effects t i h ll t 10

How Do These Apply to Our Patients? Little data also supporting CVD event reduction in primary prevention among pts >75 w/ no clinical CVD Clinical risk calculator stops at age 79 Must also consider that we are looking at a 10 yr risk of CVD, so if pt doesn t have a 10 yr life expectancy, statin therapy is not likely to be beneficial Under the guideline limitations section PROs Pros: New guidelines do identify pts for whom RCT data do not support statin therapy and have entire groups of people (>75 y/o, HD, or CHF) for whom no recommendation is made Elimination of routine LDL level assessment in pts receiving statins because target levels are not emphasized CONs Cons: Risk calculator has not been prospectively tested for accuracy and grossly overestimates CVD risk Also not validated in races other than African American or Caucasian New criteria could result in >45 million Americans (1 in 3 adults) Lancet 2013;382:1762 65. who do not have CVD to be Ridker P and Cook N. Statins: new American guidelines for prevention of cardiovascular disease. 11

This apparently seasoned integration of data and opinion eventually would lead to massive use of statins at the population level; i.e. Statinization. It is unclear whether this would be one of the greatest achievements or one of the worst disasters of medical history Ioannidis J. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. JAMA 2014;311(5):463 4. Dr. J Ioannidis, JAMA editorial Case Examples Case #1 79 y/o AAM Non diabetic, non smoker Systolic BP of 120 (not on BP meds) T chol 150, HDL 40 Calculated 10 yr risk of CVD is 13.7% Statin or not??? Case Examples Case #2 55 y/o WM Smoker, hx of HTN, non diabetic Systolic BP of 145 on antihypertensives T chol of 180 (LDL chol of 75, HDL chol of 50) Calculated 10 yr risk of CVD of 9.6% Statin or not??? 12

In Conclusion The new cholesterol guidelines do not have any recommendations for primary prevention of CVD in those >75 y/o Small amts of data for secondary prevention, but only w/ mod. intensity statins As always, must use clinical judgment in terms of risk vs. benefits and take into account As a geriatrician I look at life expectancy and quality of life In frail elders w/ multiple medical comorbidities, a statin will likely not change their disease trajectory Statins have a very limited role in my nursing home population. Exceptions are in cases of acute cardiovascular events and then the question becomes how long do I continue this after the event? 13

14